Phase 1 Study of Paclitaxel Administered Twice Weekly to Children With Refractory Solid Tumors: A Pediatric Oncology Group Study - Concepedia

Concepedia

Publication | Closed Access

Phase 1 Study of Paclitaxel Administered Twice Weekly to Children With Refractory Solid Tumors: A Pediatric Oncology Group Study

22

Citations

18

References

2003

Year

Robert J. Hayashi, Susan M. Blaney, Jim Sullivan, Steve Weitman, Teresa J. Vietti, Mark L. Bernstein

Journal of Pediatric Hematology/Oncology

Abstract

Protracted twice-weekly dosing of paclitaxel is limited by neutropenia. The maximum tolerated dose of paclitaxel administered twice weekly x 6 doses, every 28 days, was 50 mg/m2/dose.

References

	Year	Citations

Page 1